title: The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma.
abstract: OBJECTIVE
  Preliminary data on the use of autologous stem cell transplantation (ASCT) as a salvage therapy for peripheral T-cell lymphoma (PTCL) indicate that the results are similar to those obtained in aggressive B-cell lymphomas. The aim of our study was to analyze outcomes of a large series of patients with PTCL with a prolonged follow-up who received ASCT as salvage therapy.
  
  
  METHODS
  Between 1990 and 2004, 123 patients in this situation were registered in the GELTAMO database. The median age at transplantation was 43.5 years; in 91% of patients the disease was chemosensitive.
  
  
  RESULTS
  Seventy-three percent of the patients achieved complete remission, 11% partial remission and the procedure failed in 16%. At a median follow-up of 61 months, the 5-year overall and progression-free survival rates were 45% and 34%, respectively. The presence of more than one factor of the adjusted International Prognostic Index (a-IPI) and a high beta2-microglobulin at transplantation were identified as adverse prognostic factors for both overall and progression-free survival and allowed the population to be stratified into three distinct risk groups.
  
  
  CONCLUSIONS
  Our data show that approximately one third of patients with PTCL in the salvage setting may enjoy prolonged survival following ASCT, provided they are transplanted in a chemosensitive disease state. The a-IPI and beta2-microglobulin level predict the outcome after ASCT in relapsing/refractory PTCL.
authors.affiliation: Oncology Department, University Hospital Son Dureta, Palma de Mallorca, Balearic Islands, Spain. jrodriguez@hsd.es
authors.forename: José
authors.initials: J
authors.lastname: Rodríguez
authors.forename: Eulogio
authors.initials: E
authors.lastname: Conde
authors.forename: Antonio
authors.initials: A
authors.lastname: Gutiérrez
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Lahuerta
authors.forename: Reyes
authors.initials: R
authors.lastname: Arranz
authors.forename: Anna
authors.initials: A
authors.lastname: Sureda
authors.forename: Javier
authors.initials: J
authors.lastname: Zuazu
authors.forename: Alberto
authors.initials: A
authors.lastname: Fernández de Sevilla
authors.forename: Maurizio
authors.initials: M
authors.lastname: Bendandi
authors.forename: Carlos
authors.initials: C
authors.lastname: Solano
authors.forename: Angel
authors.initials: A
authors.lastname: León
authors.forename: María Rosario
authors.initials: MR
authors.lastname: Varela
authors.forename: María Dolores
authors.initials: MD
authors.lastname: Caballero
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D016026:Bone Marrow Transplantation / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000706:statistics & numerical data; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy / Q000706:statistics & numerical data; D012720:Severity of Illness Index; D016019:Survival Analysis; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D001613:beta 2-Microglobulin / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D001613:beta 2-Microglobulin